Meeting
2018 ASCO Annual Meeting
Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib.
Authors
Barry Paul
Duke University, Chapel Hill, NC
Barry Paul , Daniel Feinberg , Pasupathi Sundaramoorthy , J. Brice Weinberg , Yubin Kang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8047)
DOI
10.1200/JCO.2018.36.15_suppl.8047
Abstract #
8047
Poster Bd #
56
Abstract Disclosures
Similar Posters
First Author: Allison Distler
Poster
2014 ASCO Annual Meeting
Effect of afatinib alone and in combination with dasatinib in triple-negative breast cancer cell lines.
First Author: Mohamed F.K. Ibrahim
Poster
2014 ASCO Annual Meeting
Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide on synergistic cytotoxicity in multiple myeloma.
First Author: Dharminder Chauhan
Poster
2013 ASCO Annual Meeting
HM1.24/CD317-directed immunotoxin to eliminate malignant plasma cells in vitro and in vivo.
First Author: Martin Gramatzki